Company profile: Emmaus Medical
1.1 - Company Overview
Company description
- Provider of pharmaceutical therapies for rare diseases, including Endari, a prescription-grade L-glutamine oral powder to reduce acute complications of sickle cell disease in adults and children five years and older, and NutreStore (L-glutamine) for short bowel syndrome. Offers a full-service telehealth platform for Endari prescribing, dispensing and delivery, and is developing KM10544, a novel IRAK4 inhibitor for cancers.
Products and services
- Endari: A prescription-grade L-glutamine oral powder that reduces acute complications of sickle cell disease in adults and children five years and older
- IRAK4 Inhibitor (KM10544): A novel IRAK4 inhibitor licensed from Kainos Medicine for the treatment of cancers including leukemia, lymphoma, and solid tumors
- Telehealth Solution: A full-service telehealth platform enabling online prescribing, dispensing, and delivery of Endari through telehealth services
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Emmaus Medical
Neurona Therapeutics
HQ: United States
Website
- Description: Provider of cell therapies for neurological disorders, including NRTX-1001, a one-time dose therapy for drug-resistant focal epilepsy using human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells; myelinating glial cell therapy using human oligodendrocytes to restore myelin; and gene-edited neural cell therapies for targeted delivery to the CNS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurona Therapeutics company profile →
TScan
HQ: United States
Website
- Description: Provider of TCR-T immunotherapies and platforms for cancer, including TSC-100 and TSC-101 targeting minor histocompatibility antigens HA-1 and HA-2 for post-transplant hematologic malignancies. Offers ImmunoBank of therapeutic TCRs for multiplexed solid tumor therapies, plus TargetScan, ReceptorScan, SafetyScan, and T-Integrate for target discovery, safety screening, and non-viral manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TScan company profile →
TeraImmune
HQ: United States
Website
- Description: Provider of cell therapeutics for autoimmune diseases and immune-related disorders, using donor-derived regulatory T (Treg) cells to make Treg cells for hemophilia, multiple sclerosis, and graft-versus-host disease from stem cell transplantation, enabling the healthcare industry to suppress the unwanted immune.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TeraImmune company profile →
Ensoma
HQ: United States
Website
- Description: Provider of one-time in vivo genomic medicine solutions, including the Engenious platform for multi-cellular genome editing to engineer hematopoietic and immune cells via a single outpatient treatment; virus-like particle delivery systems devoid of viral genes with up to 35 kb payloads to minimize immune responses; smart cell therapies for cancer; and integrated tools for gene replacement, editing, endogenous protein therapies, and regulatory elements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ensoma company profile →
Aurion Biotech
HQ: United States
Website
- Description: Provider of clinical-stage cell therapies to treat ocular diseases, developing a platform targeting leading forms of blindness. Based in Seattle, Boston and Tokyo, candidates include Vyznova, a cell therapy for corneal endothelial cell dystrophies using cultured cells from a single donor, and AURN001, a combination cell therapy for corneal edema involving intracameral injection of neltependocel and Y-27632.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aurion Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Emmaus Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Emmaus Medical
2.2 - Growth funds investing in similar companies to Emmaus Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Emmaus Medical
4.2 - Public trading comparable groups for Emmaus Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →